Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • remdesivir cas1809249-37-3 manufacturer

Oct . 21, 2024 14:29 Back to list

remdesivir cas1809249-37-3 manufacturer



Remdesivir CAS 1809249-37-3 and Its Manufacturers


Remdesivir, a novel antiviral medication, has attracted significant attention since its emergence as a potential treatment for severe viral infections, particularly COVID-19

. Identified by its Chemical Abstracts Service (CAS) registry number 1809249-37-3, Remdesivir has been incorporated into treatment protocols worldwide, marking a pivotal development in combating viral diseases.

Initially developed by Gilead Sciences, Remdesivir was originally intended for the treatment of Ebola virus disease but gained prominence due to its efficacy against the SARS-CoV-2 virus, which causes COVID-19. Remdesivir works by inhibiting viral RNA polymerase, effectively halting viral replication. This mechanism is particularly critical in viral infections that lead to severe respiratory complications. The drug was granted Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) in May 2020 for the treatment of COVID-19 in hospitalized patients.


With the growing demand for Remdesivir, several manufacturers worldwide have stepped up to produce this essential medication. Gilead Sciences remains the primary manufacturer, responsible for the original formulations and supply of the drug. However, recognizing the urgent need for broader access, Gilead has engaged in licensing agreements with various generic pharmaceutical companies. These agreements allow manufacturers in multiple countries to produce and distribute authorized generics under specific conditions, thereby increasing the drug's availability at a more accessible price point.


Countries like India and Bangladesh have become key players in the production of generic versions of Remdesivir. Pharmaceutical companies in these regions, such as Cipla, Hetero Labs, and Mylan, have obtained licenses from Gilead to manufacture and sell their formulations. This initiative has been particularly vital in regions heavily impacted by the COVID-19 pandemic, where rapid access to effective treatments is crucial.


remdesivir cas1809249-37-3 manufacturer

remdesivir cas1809249-37-3 manufacturer

The production of Remdesivir involves several complex processes, including chemical synthesis and formulation development. Manufacturers must adhere to stringent quality and regulatory standards to ensure the safety and efficacy of the drug. Compliance with Good Manufacturing Practices (GMP) is essential; this not only encompasses the manufacturing environment but also the raw materials used in production.


The global demand for Remdesivir has led to intense competition among manufacturers, pushing them to optimize their production processes while ensuring affordability. As a result, the continuing development of generic formulations has enabled a greater number of patients to access this critical treatment.


Moreover, updates on research and evidence-based guidelines regarding the use of Remdesivir are ongoing. Healthcare professionals must remain informed about new studies and data regarding its efficacy, especially in different patient populations or stages of disease.


In conclusion, Remdesivir (CAS 1809249-37-3) represents a significant advancement in antiviral therapy, significantly impacting the management of severe viral infections, notably in the era of COVID-19. The collaboration between original manufacturers and generic producers has fostered a framework that enhances accessibility while maintaining quality. With continued vigilance and innovation in manufacturing practices, Remdesivir remains a vital tool in the fight against viral diseases.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
en_USEnglish
afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona sdSindhi si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu en_USEnglish